Spotlight on icosapent ethyl for cardiovascular risk reduction: Evidence to date

Xiaoming Jia, Stephanie Koh, Mahmoud Al Rifai, Roger S. Blumenthal, Salim S. Virani

Research output: Contribution to journalReview articlepeer-review

Abstract

Icosapent ethyl is a highly purified formulation of eicosapentaenoic acid, a type of omega-3 fatty acid contained in fish oil. While omega-3 fatty acids have long been thought to have cardioprotective benefits, the Reduction of Cardiovascular Events with EPA-Intervention Trial (REDUCE-IT) has helped to establish icosapent ethyl as an evidence-based therapy for risk reduction of atherosclerotic cardiovascular disease (ASCVD). REDUCE-IT, however, was by no means an overnight success story. Close examination of the evidence shows that the trial was a culmination of many lessons learned from previous studies. The purpose of this manuscript is to review contemporary evidence of icosapent ethyl in ASCVD risk reduction and the clinical implication of this promising therapy.

Original languageEnglish (US)
Pages (from-to)1-10
Number of pages10
JournalVascular health and risk management
Volume16
DOIs
StatePublished - 2020

Keywords

  • Cardiovascular outcome
  • Eicosapentaneoic acid
  • Icosapent ethyl
  • Omega-3 fatty acids

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Spotlight on icosapent ethyl for cardiovascular risk reduction: Evidence to date'. Together they form a unique fingerprint.

Cite this